Berry Genomics Co Ltd (000710.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · China · ISIN CNE000000PN7

Price
9.86 CNY
Market cap
3.49 bn CNY
P/E (2025)
–
P/S (2025)
3.75
Dividend yield
0.00 %
Net margin
-21.17 %
Return on equity (ROE)
-13.33 %
Return on assets (ROA)
-8.62 %

Berry Genomics Co Ltd financials

Fiscal year20242025
Revenue1.08 bn CNY929.82 m CNY
Gross profit474.44 m CNY401.22 m CNY
Operating income-166.61 m CNY-71.18 m CNY
EBIT-160.59 m CNY-179.58 m CNY
Net income-192.43 m CNY-196.84 m CNY
Diluted EPS – continuing operations-0.54 CNY-0.56 CNY

Full history since 1994, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Berry Genomics Co Ltd

Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor detection, technology services, equipment/reagents, laboratory overall solution, and big data services. It also offers scientific research services and medical testing services and products. In addition, the company provides GENOSi, an intelligent agent cloud platform; and NovaSeq, a next-generation sequencing platform. It serves various organizations and facilities, including hospitals, research institutions, universities, and enterprises throughout Mainland China, Hong Kong, Macau, and Taiwan. The company was founded in 1997 and is headquartered in Beijing, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.